相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba N. Gide et al.
CANCER CELL (2019)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Alexander C. Huang et al.
NATURE MEDICINE (2019)
Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer
Ivy X. Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Lu Si et al.
TRANSLATIONAL ONCOLOGY (2019)
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Felicity Newel et al.
NATURE COMMUNICATIONS (2019)
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis
Steve Lu et al.
JAMA ONCOLOGY (2019)
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
Xinan Sheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression
Anders Etzerodt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment
Lea Monteran et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Kamal Chamoun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma
Woo J. Lee et al.
MELANOMA RESEARCH (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu et al.
NATURE MEDICINE (2019)
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Ana Costa et al.
CANCER CELL (2018)
Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy
Neha Kamran et al.
CLINICAL IMMUNOLOGY (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
Alteration of the Antitumor immune Response by Cancer-Associated Fibroblasts
Linda Ziani et al.
FRONTIERS IN IMMUNOLOGY (2018)
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flavia Castro et al.
FRONTIERS IN IMMUNOLOGY (2018)
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander et al.
NATURE MEDICINE (2018)
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Li Wang et al.
NATURE COMMUNICATIONS (2018)
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon et al.
CELL (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
Teresa Davoli et al.
SCIENCE (2017)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
xCell: digitally portraying the tissue cellular heterogeneity landscape
Dvir Aran et al.
GENOME BIOLOGY (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens
Archana S. Nagaraja et al.
JCI INSIGHT (2017)
Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study
Jan H. M. Schellens et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
Naoya Yamazaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Giving AXL the axe: targeting AXL in human malignancy
Carl M. Gay et al.
BRITISH JOURNAL OF CANCER (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
CD169+ macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection
Namir Shaabani et al.
CELL DEATH & DISEASE (2016)
The biology and function of fibroblasts in cancer
Raghu Kalluri
NATURE REVIEWS CANCER (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
Stefano Ugel et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Targeting ECM disrupts cancer progression
Freja A. Venning et al.
FRONTIERS IN ONCOLOGY (2015)
Clinical significance of macrophage heterogeneity in human malignant tumors
Yoshihiro Komohara et al.
CANCER SCIENCE (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients
Mercedes Herrera et al.
CANCER SCIENCE (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Human housekeeping genes, revisited
Eli Eisenberg et al.
TRENDS IN GENETICS (2013)
Collagen VI in cancer and its biological mechanisms
Peiwen Chen et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
Helene Salmon et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance
Nobuyuki Fujii et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
Jane L. Messina et al.
SCIENTIFIC REPORTS (2012)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens
Kenichi Asano et al.
IMMUNITY (2011)
Tackling the widespread and critical impact of batch effects in high-throughput data
Jeffrey T. Leek et al.
NATURE REVIEWS GENETICS (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-α
Matthew Kraman et al.
SCIENCE (2010)
New insights into the molecular mechanism of interieukin-10-mediated immunosuppression
G Grutz
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Validation of housekeeping genes for normalizing RNA expression in real-time PCR
K Dheda et al.
BIOTECHNIQUES (2004)
Drug resistance and the microenvironment: nature and nurture
PJ Morin
DRUG RESISTANCE UPDATES (2003)
Control genes and variability: Absence of ubiquitous reference transcripts in diverse mammalian expression studies
PD Lee et al.
GENOME RESEARCH (2002)
分享论文
